These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1709224)

  • 1. Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation.
    Harder S; Thürmann P; Siewert M; Blume H; Huber T; Rietbrock N
    J Cardiovasc Pharmacol; 1991 Feb; 17(2):207-12. PubMed ID: 1709224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of food on the bioavailability of a sustained-release verapamil preparation.
    Conway EL; Phillips PA; Drummer OH; Louis WJ
    J Pharm Sci; 1990 Mar; 79(3):228-31. PubMed ID: 2338632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verapamil disposition and effect on PQ-intervals after buccal, oral and intravenous administration.
    Asthana OP; Woodcock BG; Wenchel M; Frömming KH; Schwabe L; Rietbrock N
    Arzneimittelforschung; 1984; 34(4):498-502. PubMed ID: 6540109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug input rate from the GI-tract. Michaelis-Menten kinetics and the bioavailability of slow release verapamil and nifedipine.
    Woodcock BG; Menke G; Fischer A; Köhne H; Rietbrock N
    Drug Des Deliv; 1988 May; 2(4):299-310. PubMed ID: 3255321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained-release verapamil: multiple-dose pharmacokinetic comparison of 120-mg and 240-mg tablets and the effect of halving a 240-mg tablet.
    McEwen J; Durnin C; McMurdo ME; Moreland TA
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S57-9. PubMed ID: 2475689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
    Jørgensen NP; Walstad RA
    Pharmacol Toxicol; 1988 Aug; 63(2):105-7. PubMed ID: 3186615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both.
    Karim A; Piergies A
    Clin Pharmacol Ther; 1995 Aug; 58(2):174-84. PubMed ID: 7648767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the hepatic blood flow rate model for verapamil first-pass metabolism.
    Popović J
    Eur J Drug Metab Pharmacokinet; 2007; 32(1):13-9. PubMed ID: 17479539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets.
    Moreland TA; McMurdo ME; McEwen J
    Biopharm Drug Dispos; 1989; 10(3):311-9. PubMed ID: 2720134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetic and electocardiographic study of oral verapamil sustained-release tablet in 10 Chinese volunteers].
    Liu XD; Xie L; Wang J; Zhou YS; Wang Z; Liu GQ
    Yao Xue Xue Bao; 1996; 31(7):487-91. PubMed ID: 9772689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of delayed administration of activated charcoal on the absorption of conventional and slow-release verapamil.
    Laine K; Kivistö KT; Neuvonen PJ
    J Toxicol Clin Toxicol; 1997; 35(3):263-8. PubMed ID: 9140320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of two formulations of verapamil.
    Hla KK; Henry JA; Latham AN
    Br J Clin Pharmacol; 1987 Nov; 24(5):661-4. PubMed ID: 3435694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronopharmacology of intravenous and oral modified release verapamil.
    Dilger K; Eckhardt K; Hofmann U; Kucher K; Mikus G; Eichelbaum M
    Br J Clin Pharmacol; 1999 Apr; 47(4):413-9. PubMed ID: 10233206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma concentrations of S-verapamil after single doses of two different galenic formulations of racemic verapamil.
    Harder S; Siewert M; Thürmann P; Blume H; Rietbrock N; Siewert B
    Arzneimittelforschung; 1993 May; 43(5):520-2. PubMed ID: 8328995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of bioavailability of experimental single-unit sustained release tablets of verapamil hydrochloride using the stable isotope technique.
    Marvola M; Kannikoski A; Taskinen J; Ottoila P
    J Pharm Pharmacol; 1985 Nov; 37(11):766-70. PubMed ID: 2867156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers.
    Popović J; Mitić R; Sabo A; Mikov M; Jakovljević V; Daković-Svajcer K
    Eur J Drug Metab Pharmacokinet; 2006; 31(2):87-96. PubMed ID: 16898076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.
    Ahmed JH; Godden J; Meredith PA; Elliott HL
    Br J Clin Pharmacol; 1993 Aug; 36(2):93-8. PubMed ID: 8398588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
    Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of food on the pharmacokinetics and electrocardiographic effects of sustained release verapamil in normal subjects.
    Hoon TJ; McCollam PL; Beckman KJ; Hariman RJ; Bauman JL
    Am J Cardiol; 1992 Oct; 70(11):1072-6. PubMed ID: 1414906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil.
    Berk SI; Beckman K; Hoon TJ; Hariman RJ; Hu D; Siegel FP; Bauman JL
    Pharmacotherapy; 1992; 12(1):33-9. PubMed ID: 1549537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.